EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2

Eric Mehlhaff, Devon Miller, Johnathan D Ebben, Oleksii Dobrzhanskyi, Nataliya V Uboha

Hematology/Oncology Clinics of North America · 2024

DOI: 10.1016/j.hoc.2024.02.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology/Oncology Clinics of North America, 2024. Verfasst von Eric Mehlhaff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, U…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Molecular Targeted Therapy, Stomach Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 80 Literaturangaben. Gefördert von: NCI NIH HHS, University of Wisconsin-Madison, University of Wisconsin-Madison Carbone Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastroesophageal cancers are highly diverse tumors in terms of their anatomic and molecular characteristics, making drug development challenging. Recent advancements in understanding the molecular profiles of these cancers have led to the identification of several new biomarkers. Ongoing clinical trials are investigating new targeted agents with promising results. CLDN18.2 has emerged as a biomarker with established activity of associated targeted therapies. Other targeted agents, such as bemarituzumab and DKN-01, are under active investigation. As new agents are incorporated into the treatment continuum, the questions of biomarker overlap, tumor heterogeneity, and toxicity management will need to be addressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsMolecular Targeted TherapyStomach NeoplasmsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesHumansAntineoplastic Agents

Stichwörter der Autor:innen

BiomarkerCLDN18.2DKN-01Esophageal cancerFGFR2bGastric cancerGastroesophageal junction adenocarcinomaReceptor tyrosine kinases

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsERBB2 protein, human

Autor:innen und Institutionen

  • Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA.
  • Upper Gastrointestinal Tumors Department, National Cancer Institute, Kyiv, Ukraine.
  • Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA; U…

Förderung

  • NCI NIH HHS
  • University of Wisconsin-Madison
  • University of Wisconsin-Madison Carbone Cancer Center

Zitieren

APA

Mehlhaff, E., Miller, D., Ebben, J. D., Dobrzhanskyi, O., & Uboha, N. V. (2024). Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2. Hematology/Oncology Clinics of North America. https://doi.org/10.1016/j.hoc.2024.02.006

Vancouver

Mehlhaff E, Miller D, Ebben JD, Dobrzhanskyi O, Uboha NV. Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2. Hematology/Oncology Clinics of North America. 2024. doi:10.1016/j.hoc.2024.02.006

BibTeX
@article{Mehlhaff2024,
  author = {Mehlhaff, Eric and Miller, Devon and Ebben, Johnathan D and Dobrzhanskyi, Oleksii and Uboha, Nataliya V},
  title = {Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2},
  journal = {Hematology/Oncology Clinics of North America},
  year = {2024},
  doi = {10.1016/j.hoc.2024.02.006}
}
Kostenlos starten →